Vator Securities rådger AlzeCure Pharma i 200 MSEK börsnotering
Vator Securities agerade Sole Global Coordinator och Bookrunner i det övertecknade erbjudandet i samband med AlzeCure Pharmas listning på Nasdaq First North Premier. Genom nyemissionen tillförs bolaget cirka 200 MSEK före emissionskostnader.
Läs mer
Tidningen Chef intervjuar Vator Securities vd Homan Panahi
Som sjuåring sålde han kaniner på Teherans avgasmättade gator. I dag är Homan Panahi vd för ett snabbväxande investmentföretag med 19 anställda. Målet är att förändra världen.
Läs mer
Vator Securities advises Visiopharm on a DKK100 million private placement
ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.
Läs mer
Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement
The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.
Läs mer
Vator Securities advises AlzeCure Pharma on SEK 40 million directed share issue
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 40 million.
Läs mer
Sole Bookrunner in the largest ever direct share issue in a diagnostics company in Sweden
Vator Securities Sole Bookrunner in successful SEK 324 million direct share issue in Immunovia, the largest ever in a diagnostics company in Sweden
Läs mer
Vator Securities advises Plastics Unbound on SEK 50 million Private Placement
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 50 million.
Läs mer
Vator Securities advises Ascelia Pharma on SEK 60 million Pre-IPO share issue
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 60 million.
Läs mer